Journal article
Fat mass and fat distribution are associated with low back pain intensity and disability: Results from a cohort study
SM Hussain, DM Urquhart, Y Wang, JE Shaw, DJ Magliano, AE Wluka, FM Cicuttini
Arthritis Research and Therapy | BMC | Published : 2017
Open access
Abstract
Background: Determining the association between body composition and low back pain (LBP) will improve our understanding of the mechanisms by which obesity affects LBP, and inform novel approaches to managing LBP. The aim of this study was to examine the relationship between body composition and LBP intensity and disability. Methods: A total of 5058 participants (44% men) of the Australian Diabetes, Obesity and Lifestyle Study were assessed for LBP intensity and disability using the Chronic Pain Grade Questionnaire (2013-2014). Body mass index (BMI) and waist circumference were directly obtained. Fat mass and percentage fat were estimated from bioelectrical impedance analysis at study incepti..
View full abstractGrants
Awarded by National Science Foundation
Funding Acknowledgements
For the Australian Diabetes, Obesity and Lifestyle (AusDiab) Study, funding support has been received from the National Health and Medical Research Council (NHMRC grant 233200), Australian Government Department of Health and Ageing, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service-Canberra, Department of Health and Community Services - Northern Territory, Department of Health and Human Services - Tasmania, Department of Health - New South Wales, Department of Health - Western Australia, Department of Health - South Australia, Department of Human Services - Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian and FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis, sanofi-synthelabo, and the Victorian Government's Operational Infrastructure Support (OIS) Program. SMH is the recipient of AFA-ARA Heald Fellowship funded by the Australian Rheumatology Association. DU, YW and AEW are the recipients of an NHMRC Career Development Fellowship (Clinical level 1, # 1011975 Clinical level 1, # 1065464, and Clinical level 2, # 1063574 respectively). JES is supported by an NHMRC Research Fellowship. DWD is supported by an NHMRC Senior Research Fellowship.